Hi everyone! Many thanks to the authors and experts for participating in this Q&A forum. We will be discussing the articles ‘Prospective Validation of a 21-Gene Expression Assay in Breast Cancer’ & ‘Biology before Anatomy in Early Breast Cancer’.
In the authors’ conclusions, it was noted that “among patients with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile [using this assay] had very low rates of recurrence at 5 years with endocrine therapy alone.”
To start quite open-ended, what are some initial thoughts about the results and conclusions of the study?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.